276 lines
138 KiB
Text
276 lines
138 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-toc">
|
|
<meta name="ncbi_acc" content="NBK557028">
|
|
<meta name="ncbi_domain" content="niceng155er4">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK557028/?report=reader">
|
|
<meta name="ncbi_pagename" content="Evidence review for questionnaires to assess tinnitus - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="toc">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Evidence review for questionnaires to assess tinnitus - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="1">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE,NOIMAGEINDEX">
|
|
<meta name="author" content="National Guideline Centre (UK)">
|
|
<meta name="citation_title" content="Evidence review for questionnaires to assess tinnitus">
|
|
<meta name="citation_publisher" content="National Institute for Health and Care Excellence (NICE)">
|
|
<meta name="citation_date" content="2020/03">
|
|
<meta name="citation_author" content="National Guideline Centre (UK)">
|
|
<meta name="citation_pmid" content="32437104">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK557028/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Evidence review for questionnaires to assess tinnitus">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute for Health and Care Excellence (NICE)">
|
|
<meta name="DC.Contributor" content="National Guideline Centre (UK)">
|
|
<meta name="DC.Date" content="2020/03">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK557028/">
|
|
<meta name="og:title" content="Evidence review for questionnaires to assess tinnitus">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK557028/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng155er4-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/niceng155er4/toc/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK557028/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8C49117D72A94100000000000D000D.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK557028/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-cmap-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK557028/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK557028/&text=Evidence%20review%20for%20questionnaires%20to%20assess%20tinnitus"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-cmap-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">In Page Navigation</div></div><div class="cnt lol f1"><a href="/books/n/niceercollect/?report=reader">NICE Evidence Reviews Collection</a><a class="current">Title Information</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK557028/?report=classic">Switch to classic view</a><a href="/books/n/niceng155er4/pdf/">PDF (844K)</a><a href="/books/n/niceng155er4/toc/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK557028%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8C49117D72A94100000000000D000D.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style"><div class="fm-sec bkr_bottom_sep"><div class="bkr_thumb"><a href="https://www.nice.org.uk" title="National Institute for Health and Care Excellence (NICE)" class="img_link icnblk_img" ref="pagearea=logo&targetsite=external&targetcat=link&targettype=publisher"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng155er4-lrg.png" alt="Cover of Evidence review for questionnaires to assess tinnitus" /></a></div><div class="bkr_bib"><h1 id="_NBK557028_"><span itemprop="name">Evidence review for questionnaires to assess tinnitus</span></h1><div class="subtitle">Tinnitus: assessment and management</div><p><b>Evidence review E</b></p><p><i>NICE Guideline, No. 155</i></p><p class="contrib-group"><h4>Authors</h4><span itemprop="author">National Guideline Centre (UK)</span>.</p><div class="half_rhythm">London: <a href="https://www.nice.org.uk" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=publisher"><span itemprop="publisher">National Institute for Health and Care Excellence (NICE)</span></a>; <span itemprop="datePublished">2020 Mar</span>.<div class="small">ISBN-13: <span itemprop="isbn">978-1-4731-3711-0</span></div></div><div><a href="/books/about/copyright/">Copyright</a> © NICE 2020.</div></div><div class="bkr_clear"></div></div><div id="niceng155er4.s1"><h2 id="_niceng155er4_s1_">1. Questionnaires to assess tinnitus</h2><div id="niceng155er4.s1.1"><h3>1.1. Review question: What is the most clinically and cost-effective questionnaire to assess tinnitus?</h3></div><div id="niceng155er4.s1.2"><h3>1.2. Introduction</h3><p>The only ways to assess tinnitus severity and impact currently are via a subjective measure such as a questionnaire, clinical discussion or visual analogue scales. Many tinnitus questionnaires have been developed and in this chapter consideration has been given to the clinical efficacy for each measure and their abilities to demonstrate clinical change.</p><p>Questionnaires vary in terms of the areas and detail that they cover. In addition to a standard clinical history, examination and hearing assessment, many clinicians offer psychometric questionnaires. Tinnitus can affect people’s quality of life, sleep, and mood. Questionnaires can be specifically related to tinnitus and hearing in order to evaluate tinnitus annoyance, distress and severity. Other questionnaires can be used to measure general depression, anxiety, quality of life and insomnia. No questionnaires have been developed for assessing tinnitus in children.</p><p>By assessing people’s tinnitus with a good questionnaire, the health professional and person with tinnitus are better able to develop a management plan targeted to the individual’s needs. This review has been carried out to inform recommendations about which questionnaires are most clinically and cost effective and valuable in contributing to the best possible management strategy for a person with tinnitus.</p><p>Separate reviews focus more specifically on assessment of psychological impact and quality of life (evidence reviews F and G).</p></div><div id="niceng155er4.s1.3"><h3>1.3. PICO table</h3><p>For full details see the review protocol in <a href="#niceng155er4.appa">appendix A</a>.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng155er4tab1"><a href="/books/NBK557028/table/niceng155er4.tab1/?report=objectonly" target="object" title="Table 1" class="img_link icnblk_img figpopup" rid-figpopup="figniceng155er4tab1" rid-ob="figobniceng155er4tab1"><img class="small-thumb" src="/books/NBK557028/table/niceng155er4.tab1/?report=thumb" src-large="/books/NBK557028/table/niceng155er4.tab1/?report=previmg" alt="Table 1. PICO characteristics of review question." /></a><div class="icnblk_cntnt"><h4 id="niceng155er4.tab1"><a href="/books/NBK557028/table/niceng155er4.tab1/?report=objectonly" target="object" rid-ob="figobniceng155er4tab1">Table 1</a></h4><p class="float-caption no_bottom_margin">PICO characteristics of review question. </p></div></div></div><div id="niceng155er4.s1.4"><h3>1.4. Clinical evidence</h3><div id="niceng155er4.s1.4.1"><h4>1.4.1. Included studies</h4><p>No relevant randomised controlled trial evidence comparing tinnitus questionnaires with other tinnitus questionnaires or standard care (history and physical examination) were identified. Consequently, non-randomised comparative studies were also assessed. However, no relevant studies were identified for inclusion.</p></div><div id="niceng155er4.s1.4.2"><h4>1.4.2. Excluded studies</h4><p>See the excluded studies list in <a href="#niceng155er4.appi">appendix I</a>.</p></div></div><div id="niceng155er4.s1.5"><h3>1.5. Economic evidence</h3><div id="niceng155er4.s1.5.1"><h4>1.5.1. Included studies</h4><p>No relevant health economic studies were identified.</p></div><div id="niceng155er4.s1.5.2"><h4>1.5.2. Excluded studies</h4><p>No health economic studies that were relevant to this question were excluded due to assessment of limited applicability or methodological limitations.</p><p>See also the health economic study selection flow chart in <a href="#niceng155er4.appg">appendix G</a>.</p></div></div><div id="niceng155er4.s1.6"><h3>1.6. Evidence statements</h3><div id="niceng155er4.s1.6.1"><h4>1.6.1. Clinical evidence statements</h4><ul><li class="half_rhythm"><div>No relevant published evidence was identified.</div></li></ul></div><div id="niceng155er4.s1.6.2"><h4>1.6.2. Health economic evidence statements</h4><ul><li class="half_rhythm"><div>No relevant economic evaluations were identified.</div></li></ul></div></div><div id="niceng155er4.s1.7"><h3>1.7. The committee’s discussion of the evidence</h3><div id="niceng155er4.s1.7.1"><h4>1.7.1. Interpreting the evidence</h4><div id="niceng155er4.s1.7.1.1"><h5>1.7.1.1. The outcomes that matter most</h5><p>Tinnitus distress, annoyance and tinnitus severity were critical outcomes as they were thought to be common factors for people with tinnitus and impact their quality of life. Quality of life (tinnitus-related) and general quality of life were also critical outcomes due to their impact on the person with tinnitus.</p><p>Tinnitus loudness, anxiety, depression, sleep, safety, tolerability and side effects were thought to be important outcomes.</p><p>There was no outcome data for any of the outcomes.</p><p>The committee did not prioritise diagnostic accuracy outcomes such as sensitivity and specificity because they felt it was more useful to know about the effect on tinnitus outcomes and cost effectiveness of using questionnaires in the pathway.</p></div><div id="niceng155er4.s1.7.1.2"><h5>1.7.1.2. The quality of the evidence</h5><p>Randomised controlled trials (RCTs) and systematic reviews of RCTs were searched for and assessed for eligibility but no relevant RCT evidence was identified which matched the review protocol. Consequently, non-randomised comparative studies were also searched for and assessed for eligibility. No relevant non-randomised comparative studies which met the protocol were identified.</p></div><div id="niceng155er4.s1.7.1.3"><h5>1.7.1.3. Benefits and harms</h5><p>Our review found no evidence that has evaluated the clinical effectiveness of questionnaires to assess tinnitus. The committee noted that whilst no evidence was identified this is a crucial part of the management pathway and therefore consensus recommendations were made.</p><p>It was discussed that there are many questionnaires used to assess tinnitus in adults in the UK, the most commonly used questionnaires being the THI, TFI, TQ and Mini-TQ.</p><p>The committee noted that out of the most commonly used questionnaires; TFI provides the broadest assessment of the impact of tinnitus with domains covering a variety of components and it can be used to measure change. The THI, whilst covering a variety of domains, has more of a focus on psychological aspects. The committee felt that if more information is required about the psychological impact of tinnitus, the TQ or Mini-TQ would be appropriate and should inform decisions about referral for psychological therapies (see evidence review L).</p><p>These questionnaires have the benefit of taking a measure of the impact of a person’s tinnitus and allowing a more informed discussion with the person of potential management strategies. They sometimes can help to spot false positives. There are minimal harms associated with questionnaires. Whilst they take some time to complete, this is outweighed by the benefits to the future management strategy.</p><p>Current practice is that questionnaires to assess tinnitus are mainly completed within services such as ENT and audiology, with people referred for tinnitus that bothers them. Assessment of tinnitus in general practice is currently patchy and may often only include looking in the ears and history-taking. The committee decided to make a research recommendation to examine the optimal method for assessing tinnitus in general practice (including consultation questions, physical examinations and questionnaires).</p><p>The use of questionnaires should be particularly considered before-and-after interventions have been initiated, to assess the impact of tinnitus and the benefits of the interventions. The committee noted that questionnaires can be used as a decision-aid for healthcare professionals to assist in discussions around tailoring management strategies with the person.</p><p>The committee discussed that whilst there are no specific questionnaires to assess tinnitus in children and young people, it is important that age-appropriate measures are used. Measures can include goal-based measures such as a visual analogue scale, for example the ‘tinnitus thermometer’. A consensus recommendation was made for this population.</p><p>The committee wanted to encourage research into age-appropriate questionnaires (in particular the designing of questionnaires and subsequent evaluation) for children and young people and made a research recommendation. They hope that this will inform future updates of the guideline by allowing more specific recommendations to be made.</p><p>No evidence was identified that evaluated the use of questionnaires for the assessment of tinnitus with people with learning disability, cognitive impairment or visual impairment. Whilst the prevalence of tinnitus in these populations in the UK is unknown, the committee discussed the need for ensuring that these populations are appropriately assessed and made a consensus recommendation to use other measures such as visual analogue scales. The committee noted that there are two types of visual analogue scales that can be useful: how much does your tinnitus bother you and how much does the tinnitus interfere with what you do?</p><p>The committee made a research recommendation to encourage research into ability-appropriate questionnaires.</p><p>The committee also noted that there was no evidence for the use of tinnitus questionnaires for people who are d/Deaf or who have a severe-to-profound hearing loss. Identifying clinically effective tinnitus questionnaires would enable this population to receive relevant assessment of their tinnitus and allow consideration to be given to how to optimally manage tinnitus. The committee agreed that a research recommendation is made for the use of tinnitus questionnaires for this population (see <a href="#niceng155er4.appi">Appendix I</a>:).</p><p>Lay representatives on the committee noted that it is crucial that questionnaire results are discussed with people with tinnitus. Healthcare professionals should discuss the results and how the questionnaire findings inform possible management (as described in the recommendations for tinnitus support (see Evidence review A: tinnitus support). This will enable people with tinnitus to feel fully engaged with their care and make informed decisions about interventions that are most appropriate for them.</p></div></div><div id="niceng155er4.s1.7.2"><h4>1.7.2. Cost effectiveness and resource use</h4><p>There were no economic evaluations or clinical evidence available to support the use of one questionnaire over another. The committee therefore used their clinical experience to form a consensus recommendation that the TFI should be used as an initial assessment tool for adults due to its ability to provide a wide breadth of information about the impact of tinnitus. While other questionnaires are available, the committee explained the TFI is the only tinnitus questionnaire which has been designed to measure change and therefore it was specifically named as the preferred questionnaire in the recommendation. There was also the view that recommending a single questionnaire would help standardise practice.</p><p>The committee were conscious of the potential resource impact of completing and discussing these questionnaires in general practice where general practitioners are limited on time. In the absence of clinical and economic evidence, the committee opted for a research recommendation to identify the most clinical and cost-effectiveness methods of assessing tinnitus in general practice. The committee were of the view that using the TFI would be cost-neutral because the TFI is freely available and mostly completed outside the consultation room with only the results discussed with the clinician. Therefore, extra staff time is not required to complete the TFI. In the absence of the questionnaire, the committee indicated that a clinician would still have to enquire about the impact of tinnitus on the lives of people with tinnitus. If this enquiry was sufficiently comprehensive, it would require the same amount of staff time as discussing the results of the TFI. Therefore, using the TFI would provide a clearer structure for the relevant questions that should be asked and would help to standardise practice. The committee highlighted it was important to measure the impact and benefit of interventions so that alternative strategies could be employed to help a person with bothersome tinnitus. As people with tinnitus will already be expected to attend a post-intervention appointment and this recommendation will not require an additional consultation, this component of the recommendation is not expected to result in an additional expenditure.</p><p>Finally, those instances where the use of a questionnaire is not feasible (due to age, lack of comprehension or other reasons) a recommendation was made to use the visual analogue scale (VAS) before and after intervention. VAS can be completed relatively quickly and would not result in significant staff costs. The committee have also made two research recommendations to identify the most clinical and cost-effective questionnaire, the first for children and young people and the second for those with learning disabilities.</p></div><div id="niceng155er4.s1.7.3"><h4>1.7.3. Other factors the committee took into account</h4><p>The committee noted that questionnaires may not be accessible for every person, for example, in the case of visual or cognitive impairment or learning disability, or where language is a barrier. In these cases clinicians may use alternative methods to establish the impact of tinnitus and the effectiveness of interventions, such as visual analogue scales. The committee made a research recommendation to establish the most clinically and cost effective questionnaire to assess tinnitus in people with learning disability or cognitive impairment.</p><p>The lay representatives on the committee noted that there is a perception that people are sometimes dismissed, being told there is nothing that can be done to help. The committee made a research recommendation that further work should be conducted on the optimal method for assessing tinnitus in general practice (including consultation questions, physical examinations and questionnaires).</p></div></div></div><div id="niceng155er4.rl.r1"><h2 id="_niceng155er4_rl_r1_">References</h2><dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>1.</dt><dd><div class="bk_ref" id="niceng155er4.ref1">Aazh
|
|
H, Moore
|
|
BCJ. Usefulness of self-report questionnaires for psychological assessment of patients with tinnitus and hyperacusis and patients’ views of the questionnaires. International Journal of Audiology. 2017; 56(7):489–498 [<a href="https://pubmed.ncbi.nlm.nih.gov/28277857" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28277857</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>2.</dt><dd><div class="bk_ref" id="niceng155er4.ref2">Baguley
|
|
DM, Humphriss
|
|
RL, Hodgson
|
|
CA. Convergent validity of the tinnitus handicap inventory and the tinnitus questionnaire. Journal of Laryngology and Otology. 2000; 114(11):840–843 [<a href="https://pubmed.ncbi.nlm.nih.gov/11144832" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11144832</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>3.</dt><dd><div class="bk_ref" id="niceng155er4.ref3">Ciocon
|
|
JO, Amede
|
|
F, Lechtenberg
|
|
C, Astor
|
|
F. Tinnitus: A stepwise workup to quiet the noise within. Geriatrics. 1995; 50(2):18–25 [<a href="https://pubmed.ncbi.nlm.nih.gov/7835722" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7835722</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>4.</dt><dd><div class="bk_ref" id="niceng155er4.ref4">Department of Health. Provision of services for adults with tinnitus: A good practice guide. Department of Health, 2009. Available from: <a href="https://webarchive.nationalarchives.gov.uk/20130124045237/http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_093810.pdf" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">https://webarchive<wbr style="display:inline-block"></wbr>​.nationalarchives<wbr style="display:inline-block"></wbr>​.gov.uk<wbr style="display:inline-block"></wbr>​/20130124045237/http://www<wbr style="display:inline-block"></wbr>​.dh.gov.uk/prod_consum_dh<wbr style="display:inline-block"></wbr>​/groups<wbr style="display:inline-block"></wbr>​/dh_digitalassets/documents<wbr style="display:inline-block"></wbr>​/digitalasset/dh_093810.pdf</a></div></dd></dl><dl class="bkr_refwrap"><dt>5.</dt><dd><div class="bk_ref" id="niceng155er4.ref5">Fackrell
|
|
K, Hall
|
|
DA, Barry
|
|
JG, Hoare
|
|
DJ. Performance of the Tinnitus Functional Index as a diagnostic instrument in a UK clinical population. Hearing Research. 2018; 358:74–85 [<a href="https://pubmed.ncbi.nlm.nih.gov/29129348" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29129348</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>6.</dt><dd><div class="bk_ref" id="niceng155er4.ref6">Jüris
|
|
L, Ekselius
|
|
L, Andersson
|
|
G, Larsen
|
|
HC. The Hyperacusis Questionnaire, loudness discomfort levels, and the Hospital Anxiety and Depression Scale: A cross-sectional study. Hearing, Balance & Communication. 2013; 11(1/2):72–79</div></dd></dl><dl class="bkr_refwrap"><dt>7.</dt><dd><div class="bk_ref" id="niceng155er4.ref7">McFerran
|
|
D, Hoare
|
|
DJ, Carr
|
|
S, Ray
|
|
J, Stockdale
|
|
D. Tinnitus services in the United Kingdom: a survey of patient experiences. BMC Health Services Research. 2018; 18:110 [<a href="/pmc/articles/PMC5809968/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5809968</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29433479" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29433479</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>8.</dt><dd><div class="bk_ref" id="niceng155er4.ref8">National Institute for Health and Care Excellence. Developing NICE guidelines: the manual [Updated October 2018]
|
|
London. National Institute for Health and Care Excellence, 2014. Available from: <a href="https://www.nice.org.uk/process/pmg20/chapter/introduction-and-overview" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">https://www<wbr style="display:inline-block"></wbr>​.nice.org<wbr style="display:inline-block"></wbr>​.uk/process/pmg20/chapter<wbr style="display:inline-block"></wbr>​/introduction-and-overview</a></div></dd></dl><dl class="bkr_refwrap"><dt>9.</dt><dd><div class="bk_ref" id="niceng155er4.ref9">Newman
|
|
CW, Jacobson
|
|
GP, Spitzer
|
|
JB. Development of the tinnitus handicap inventory. Archives of Otolaryngology - Head and Neck Surgery. 1996; 122(2):143–148 [<a href="https://pubmed.ncbi.nlm.nih.gov/8630207" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8630207</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>10.</dt><dd><div class="bk_ref" id="niceng155er4.ref10">Schlee
|
|
W, Pryss
|
|
RC, Probst
|
|
T, Schobel
|
|
J, Bachmeier
|
|
A, Reichert
|
|
M
|
|
et al. Measuring the moment-to-moment variability of tinnitus: The TrackYourTinnitus smart phone app. Frontiers in Aging Neuroscience. 2016; 8:294 [<a href="/pmc/articles/PMC5156957/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5156957</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28018210" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28018210</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>11.</dt><dd><div class="bk_ref" id="niceng155er4.ref11">Searchfield
|
|
GD, Jerram
|
|
C, Wise
|
|
K, Raymond
|
|
S. The impact of hearing loss on tinnitus severity. Australian and New Zealand Journal of Audiology. 2007; 29(2):67–76</div></dd></dl><dl class="bkr_refwrap"><dt>12.</dt><dd><div class="bk_ref" id="niceng155er4.ref12">Stockdale
|
|
D, McFerran
|
|
D, Brazier
|
|
P, Pritchard
|
|
C, Kay
|
|
T, Dowrick
|
|
C
|
|
et al. An economic evaluation of the healthcare cost of tinnitus management in the UK. BMC Health Services Research. 2017; 17:577 [<a href="/pmc/articles/PMC5567641/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5567641</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28830503" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28830503</span></a>]</div></dd></dl></dl></div><div id="appendixesappgroup1"><h2 id="_appendixesappgroup1_">Appendices</h2><div id="niceng155er4.appa"><h3>Appendix A. Review protocols</h3><p id="niceng155er4.appa.et1"><a href="/books/NBK557028/bin/niceng155er4-appa-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Table 2. Review protocol: What is the most clinically and cost-effective questionnaire to assess tinnitus?</a><span class="small"> (PDF, 348K)</span></p><p id="niceng155er4.appa.tab1"><a href="/books/NBK557028/table/niceng155er4.appa.tab1/?report=objectonly" target="object" rid-ob="figobniceng155er4appatab1" class="figpopup">Table 3. Health economic review protocol</a></p></div><div id="niceng155er4.appb"><h3>Appendix B. Literature search strategies</h3><p>The literature searches for this review are detailed below and complied with the methodology outlined in Developing NICE guidelines: the manual.<a class="bibr" href="#niceng155er4.ref8" rid="niceng155er4.ref8"><sup>8</sup></a></p><p><i>For more detailed information, please see the</i>
|
|
<a href="/books/NBK557028/bin/niceng155er4_bm1.pdf">Methodology Review</a>.</p><div id="niceng155er4.appb.s1"><h4>B.1. Clinical search literature search strategy</h4><p>Searches were constructed using a PICO framework where population (P) terms were combined with Intervention (I) and in some cases Comparison (C) terms. Outcomes (O) are rarely used in search strategies for interventions as these concepts may not be well described in title, abstract or indexes and therefore difficult to retrieve. Search filters were applied to the search where appropriate.</p><p id="niceng155er4.appb.tab1"><a href="/books/NBK557028/table/niceng155er4.appb.tab1/?report=objectonly" target="object" rid-ob="figobniceng155er4appbtab1" class="figpopup">Table 4. Database date parameters and filters used</a></p><p id="niceng155er4.appb.tab2"><a href="/books/NBK557028/table/niceng155er4.appb.tab2/?report=objectonly" target="object" rid-ob="figobniceng155er4appbtab2" class="figpopup">Medline (Ovid) search terms</a></p><p id="niceng155er4.appb.tab3"><a href="/books/NBK557028/table/niceng155er4.appb.tab3/?report=objectonly" target="object" rid-ob="figobniceng155er4appbtab3" class="figpopup">Embase (Ovid) search terms</a></p><p id="niceng155er4.appb.tab4"><a href="/books/NBK557028/table/niceng155er4.appb.tab4/?report=objectonly" target="object" rid-ob="figobniceng155er4appbtab4" class="figpopup">Cochrane Library (Wiley) search terms</a></p><p id="niceng155er4.appb.tab5"><a href="/books/NBK557028/table/niceng155er4.appb.tab5/?report=objectonly" target="object" rid-ob="figobniceng155er4appbtab5" class="figpopup">CINAHL (EBSCO) search terms</a></p></div><div id="niceng155er4.appb.s2"><h4>B.2. Health Economics literature search strategy</h4><p>Health economic evidence was identified by conducting a broad search relating to the tinnitus population in NHS Economic Evaluation Database (NHS EED – this ceased to be updated after March 2015) and the Health Technology Assessment database (HTA) with no date restrictions. NHS EED and HTA databases are hosted by the Centre for Research and Dissemination (CRD). Additional searches were run on Medline and Embase for health economics and quality of life studies.</p><p id="niceng155er4.appb.tab6"><a href="/books/NBK557028/table/niceng155er4.appb.tab6/?report=objectonly" target="object" rid-ob="figobniceng155er4appbtab6" class="figpopup">Table 5. Database date parameters and filters used</a></p><p id="niceng155er4.appb.tab7"><a href="/books/NBK557028/table/niceng155er4.appb.tab7/?report=objectonly" target="object" rid-ob="figobniceng155er4appbtab7" class="figpopup">Medline (Ovid) search terms</a></p><p id="niceng155er4.appb.tab8"><a href="/books/NBK557028/table/niceng155er4.appb.tab8/?report=objectonly" target="object" rid-ob="figobniceng155er4appbtab8" class="figpopup">Embase (Ovid) search terms</a></p><p id="niceng155er4.appb.tab9"><a href="/books/NBK557028/table/niceng155er4.appb.tab9/?report=objectonly" target="object" rid-ob="figobniceng155er4appbtab9" class="figpopup">NHS EED and HTA (CRD) search terms</a></p></div></div><div id="niceng155er4.appc"><h3>Appendix C. Clinical evidence selection</h3><p id="niceng155er4.appc.fig1"><a href="/books/NBK557028/figure/niceng155er4.appc.fig1/?report=objectonly" target="object" rid-ob="figobniceng155er4appcfig1" class="figpopup">Figure 1. Flow chart of clinical study selection for the review of what is the most clinically and cost-effective questionnaire to assess tinnitus</a></p></div><div id="niceng155er4.appd"><h3>Appendix D. Clinical evidence tables</h3><p>No evidence identified.</p></div><div id="niceng155er4.appe"><h3>Appendix E. Forest plots</h3><p>No evidence identified.</p></div><div id="niceng155er4.appf"><h3>Appendix F. GRADE tables</h3><p>No evidence identified.</p></div><div id="niceng155er4.appg"><h3>Appendix G. Health economic evidence selection</h3><p id="niceng155er4.appg.fig1"><a href="/books/NBK557028/figure/niceng155er4.appg.fig1/?report=objectonly" target="object" rid-ob="figobniceng155er4appgfig1" class="figpopup">Figure 2. Flow chart of health economic study selection for the guideline</a></p></div><div id="niceng155er4.apph"><h3>Appendix H. Excluded studies</h3><div id="niceng155er4.apph.s1"><h4>H.1. Excluded clinical studies</h4><p id="niceng155er4.apph.tab1"><a href="/books/NBK557028/table/niceng155er4.apph.tab1/?report=objectonly" target="object" rid-ob="figobniceng155er4apphtab1" class="figpopup">Table 6. Studies excluded from the clinical review</a></p></div><div id="niceng155er4.apph.s2"><h4>H.2. Excluded health economic studies</h4><p>None.</p></div></div><div id="niceng155er4.appi"><h3>Appendix I. Research recommendations</h3><div id="niceng155er4.appi.s1"><h4>I.1. Method for assessing tinnitus in general practice</h4><div id="niceng155er4.appi.s1.1"><h5>Research question: What is the optimal method for assessing tinnitus in general practice (including consultation questions, physical examinations and questionnaires)?</h5><p>
|
|
<b>Why this is important:</b>
|
|
</p><p>There is currently uncertainty about the approach that should be taken when assessing people with tinnitus in general practice in the UK. There is an urgent need for standardisation of assessment in general practice. Once a method for assessing tinnitus has been identified, training on how to use the optimal method can be integrated within GP training so that GPs are well-equipped to deal with the high volume of people presenting with tinnitus.</p><p>Consequently, people with tinnitus will have a more positive experience in general practice and will be referred appropriately in line with the recommendations.</p><p id="niceng155er4.appi.tab1"><a href="/books/NBK557028/table/niceng155er4.appi.tab1/?report=objectonly" target="object" rid-ob="figobniceng155er4appitab1" class="figpopup">Criteria for selecting high-priority research recommendations</a></p></div></div><div id="niceng155er4.appi.s2"><h4>I.2. Tinnitus questionnaires for children and young people</h4><div id="niceng155er4.appi.s2.1"><h5>Research question: What is the most clinically and cost-effective tinnitus questionnaire to assess tinnitus in children and young people?</h5><p>
|
|
<b>Why this is important:</b>
|
|
</p><p>Children and young people commonly experience tinnitus, but this symptom is often unreported and the evidence base to support the assessment and management of tinnitus in children is lacking. The evaluation of a paediatric tinnitus assessment instrument is of vital importance to allow an appropriate appraisal of tinnitus burden, to allow triage, and to monitor change (i.e. outcomes of management strategies). The committee were unaware of existing questionnaires and so new research should develop and test questionnaires for children and young people with tinnitus.</p><p id="niceng155er4.appi.tab2"><a href="/books/NBK557028/table/niceng155er4.appi.tab2/?report=objectonly" target="object" rid-ob="figobniceng155er4appitab2" class="figpopup">Criteria for selecting high-priority research recommendations</a></p></div></div><div id="niceng155er4.appi.s3"><h4>I.3. Tinnitus questionnaires for people with a learning disability or cognitive impairment</h4><div id="niceng155er4.appi.s3.1"><h5><b>Research question:</b> What is the most clinically and cost-effective tinnitus questionnaire to assess tinnitus in people with a learning disability or cognitive impairment?</h5><p>
|
|
<b>Why this is important:</b>
|
|
</p><p>There is currently variation in how tinnitus is assessed in people with learning disability or cognitive impairment. It is important that effective tinnitus questionnaires for this population are identified to ensure that healthcare professionals are well-equipped and that care is standardised across the UK. Use of an effective questionnaire can consequently inform the development of a management plan, allow an appropriate appraisal of tinnitus burden, to allow triage, and to monitor change (i.e. outcomes of management strategies). The committee were unaware of existing questionnaires and so new research should develop and test questionnaires for people with learning disability or cognitive impairment with tinnitus.</p><p id="niceng155er4.appi.tab3"><a href="/books/NBK557028/table/niceng155er4.appi.tab3/?report=objectonly" target="object" rid-ob="figobniceng155er4appitab3" class="figpopup">Criteria for selecting high-priority research recommendations</a></p></div></div><div id="niceng155er4.appi.s4"><h4>I.4. Tinnitus questionnaires in people who are d/Deaf or who have a severe-to-profound hearing loss</h4><div id="niceng155er4.appi.s4.1"><h5>Research question: What is the most clinically and cost-effective tinnitus questionnaire to assess tinnitus in people who are d/Deaf or who have a severe-to-profound hearing loss?</h5><p>
|
|
<b>Why this is important:</b>
|
|
</p><p>Many tinnitus questionnaires contain questions related to the effect of tinnitus on communication, social or work activities or distress from communication problems attributed to tinnitus. However, as hearing loss can also have an impact in these situations, it can be difficult to separate the effect of hearing loss from that solely due to tinnitus. In addition, questions on tinnitus and communication difficulties may not be applicable to those whose mode of communication is sign as they are biased towards verbal communication. This research question seeks to identify the most effective questionnaire in those with a severe-to-profound hearing loss.</p><p id="niceng155er4.appi.tab4"><a href="/books/NBK557028/table/niceng155er4.appi.tab4/?report=objectonly" target="object" rid-ob="figobniceng155er4appitab4" class="figpopup">Criteria for selecting high-priority research recommendations</a></p></div></div></div></div></div><div class="fm-sec"><div><p>Final</p></div><div><p>Intervention evidence review</p><p>This evidence review was developed by the National Guideline Centre</p></div><div><p><b>Disclaimer:</b> The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.</p><p>Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.</p><p>NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the <a href="http://wales.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Welsh Government</a>, <a href="http://www.scotland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Scottish Government</a>, and <a href="http://www.northernireland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Northern Ireland Executive</a>. All NICE guidance is subject to regular review and may be updated or withdrawn.</p></div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © NICE 2020.</div><div class="small"><span class="label">Bookshelf ID: NBK557028</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32437104" title="PubMed record of this title" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">32437104</a></span></div></div><div class="small-screen-prev"></div><div class="small-screen-next"></div></article><article data-type="table-wrap" id="figobniceng155er4tab1"><div id="niceng155er4.tab1" class="table"><h3><span class="label">Table 1</span><span class="title">PICO characteristics of review question</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK557028/table/niceng155er4.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng155er4.tab1_lrgtbl__"><table><tbody><tr><th id="hd_b_niceng155er4.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Population</th><td headers="hd_b_niceng155er4.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>People presenting to a healthcare setting with tinnitus</p>
|
|
<p>Strata: children/young people and adults</p>
|
|
</td></tr><tr><th id="hd_b_niceng155er4.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Intervention(s)</th><td headers="hd_b_niceng155er4.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Questionnaires:
|
|
<ul><li class="half_rhythm"><div>Validated questionnaire for the assessment of tinnitus severity:
|
|
<ul class="circle"><li class="half_rhythm"><div>Tinnitus questionnaire (TQ)</div></li><li class="half_rhythm"><div>Tinnitus handicap inventory (THI)</div></li><li class="half_rhythm"><div>Tinnitus handicap questionnaire (THQ)</div></li><li class="half_rhythm"><div>Tinnitus reaction questionnaire (TRQ)</div></li><li class="half_rhythm"><div>Tinnitus functional index (TFI)</div></li><li class="half_rhythm"><div>Mini TQ</div></li><li class="half_rhythm"><div>International tinnitus inventory</div></li></ul></div></li></ul></td></tr><tr><th id="hd_b_niceng155er4.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparison(s)</th><td headers="hd_b_niceng155er4.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Standard care (history and physical examination)</div></li><li class="half_rhythm"><div>Compared to each other</div></li></ul></td></tr><tr><th id="hd_b_niceng155er4.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcomes</th><td headers="hd_b_niceng155er4.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Tinnitus severity (critical)</div></li></ul>
|
|
Impact of tinnitus (critical):
|
|
<ul><li class="half_rhythm"><div>Tinnitus distress</div></li><li class="half_rhythm"><div>Tinnitus annoyance</div></li></ul>
|
|
Health related QoL(critical):
|
|
<ul><li class="half_rhythm"><div>QoL (tinnitus)</div></li><li class="half_rhythm"><div>QoL</div></li></ul>
|
|
Tinnitus percept (important):
|
|
<ul><li class="half_rhythm"><div>Tinnitus loudness</div></li></ul>
|
|
Other co-occurring complaints (important):
|
|
<ul><li class="half_rhythm"><div>Depression</div></li><li class="half_rhythm"><div>Anxiety</div></li><li class="half_rhythm"><div>Anxiety and depression</div></li><li class="half_rhythm"><div>Sleep</div></li></ul>
|
|
Adverse events (important):
|
|
<ul><li class="half_rhythm"><div>Safety</div></li><li class="half_rhythm"><div>Tolerability</div></li><li class="half_rhythm"><div>Side effects</div></li></ul></td></tr><tr><th id="hd_b_niceng155er4.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study design</th><td headers="hd_b_niceng155er4.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Systematic review of RCTs</div></li><li class="half_rhythm"><div>RCT</div></li><li class="half_rhythm"><div>If there is an inadequate amount of RCT data, non-randomised comparative studies will be considered.</div></li></ul></td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng155er4appatab1"><div id="niceng155er4.appa.tab1" class="table"><h3><span class="label">Table 3</span><span class="title">Health economic review protocol</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK557028/table/niceng155er4.appa.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng155er4.appa.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_niceng155er4.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Review question</th><th id="hd_h_niceng155er4.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">All questions – health economic evidence</th></tr></thead><tbody><tr><td headers="hd_h_niceng155er4.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Objectives</b>
|
|
</td><td headers="hd_h_niceng155er4.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">To identify health economic studies relevant to any of the review questions.</td></tr><tr><td headers="hd_h_niceng155er4.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Search criteria</b>
|
|
</td><td headers="hd_h_niceng155er4.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Populations, interventions and comparators must be as specified in the clinical review protocol above.</div></li><li class="half_rhythm"><div>Studies must be of a relevant health economic study design (cost–utility analysis, cost-effectiveness analysis, cost–benefit analysis, cost–consequences analysis, comparative cost analysis).</div></li><li class="half_rhythm"><div>Studies must not be a letter, editorial or commentary, or a review of health economic evaluations. (Recent reviews will be ordered although not reviewed. The bibliographies will be checked for relevant studies, which will then be ordered.)</div></li><li class="half_rhythm"><div>Unpublished reports will not be considered unless submitted as part of a call for evidence.</div></li><li class="half_rhythm"><div>Studies must be in English.</div></li></ul></td></tr><tr><td headers="hd_h_niceng155er4.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Search strategy</b>
|
|
</td><td headers="hd_h_niceng155er4.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">A health economic study search will be undertaken using population-specific terms and a health economic study filter – see <a href="#niceng155er4.appb">appendix B</a> below.</td></tr><tr><td headers="hd_h_niceng155er4.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Review strategy</b>
|
|
</td><td headers="hd_h_niceng155er4.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">
|
|
<p>Studies not meeting any of the search criteria above will be excluded. Studies published before 2003, abstract-only studies and studies from non-OECD countries or the USA will also be excluded.</p>
|
|
<p>Each remaining study will be assessed for applicability and methodological limitations using the NICE economic evaluation checklist which can be found in appendix H of Developing NICE guidelines: the manual (2014).<a class="bibr" href="#niceng155er4.ref8" rid="niceng155er4.ref8"><sup>8</sup></a></p>
|
|
<p><b>Inclusion and exclusion criteria</b>
|
|
<ul><li class="half_rhythm"><div>If a study is rated as both ‘Directly applicable’ and with ‘Minor limitations’ then it will be included in the guideline. A health economic evidence table will be completed and it will be included in the health economic evidence profile.</div></li><li class="half_rhythm"><div>If a study is rated as either ‘Not applicable’ or with ‘Very serious limitations’ then it will usually be excluded from the guideline. If it is excluded then a health economic evidence table will not be completed and it will not be included in the health economic evidence profile.</div></li><li class="half_rhythm"><div>If a study is rated as ‘Partially applicable’, with ‘Potentially serious limitations’ or both then there is discretion over whether it should be included.</div></li></ul>
|
|
<b>Where there is discretion</b></p>
|
|
<p>The health economist will make a decision based on the relative applicability and quality of the available evidence for that question, in discussion with the guideline committee if required. The ultimate aim is to include health economic studies that are helpful for decision-making in the context of the guideline and the current NHS setting. If several studies are considered of sufficiently high applicability and methodological quality that they could all be included, then the health economist, in discussion with the committee if required, may decide to include only the most applicable studies and to selectively exclude the remaining studies. All studies excluded on the basis of applicability or methodological limitations will be listed with explanation in the excluded health economic studies appendix below.</p>
|
|
<p>The health economist will be guided by the following hierarchies.</p>
|
|
<p><i>Setting:</i>
|
|
<ul><li class="half_rhythm"><div>UK NHS (most applicable).</div></li><li class="half_rhythm"><div>OECD countries with predominantly public health insurance systems (for example, France, Germany, Sweden).</div></li><li class="half_rhythm"><div>OECD countries with predominantly private health insurance systems (for example, Switzerland).</div></li><li class="half_rhythm"><div>Studies set in non-OECD countries or in the USA will be excluded before being assessed for applicability and methodological limitations.</div></li></ul>
|
|
<i>Health economic study type:</i>
|
|
<ul><li class="half_rhythm"><div>Cost–utility analysis (most applicable).</div></li><li class="half_rhythm"><div>Other type of full economic evaluation (cost–benefit analysis, cost-effectiveness analysis, cost–consequences analysis).</div></li><li class="half_rhythm"><div>Comparative cost analysis.</div></li><li class="half_rhythm"><div>Non-comparative cost analyses including cost-of-illness studies will be excluded before being assessed for applicability and methodological limitations.</div></li></ul>
|
|
<i>Year of analysis:</i>
|
|
<ul><li class="half_rhythm"><div>The more recent the study, the more applicable it will be.</div></li><li class="half_rhythm"><div>Studies published in 2003 or later but that depend on unit costs and resource data entirely or predominantly from before 2003 will be rated as ‘Not applicable’.</div></li><li class="half_rhythm"><div>Studies published before 2003 will be excluded before being assessed for applicability and methodological limitations.</div></li></ul>
|
|
<i>Quality and relevance of effectiveness data used in the health economic analysis:</i>
|
|
<ul><li class="half_rhythm"><div>The more closely the clinical effectiveness data used in the health economic analysis match with the outcomes of the studies included in the clinical review the more useful the analysis will be for decision-making in the guideline.</div></li></ul></p>
|
|
</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng155er4appbtab1"><div id="niceng155er4.appb.tab1" class="table"><h3><span class="label">Table 4</span><span class="title">Database date parameters and filters used</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK557028/table/niceng155er4.appb.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng155er4.appb.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_niceng155er4.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Database</th><th id="hd_h_niceng155er4.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dates searched</th><th id="hd_h_niceng155er4.appb.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Search filter used</th></tr></thead><tbody><tr><td headers="hd_h_niceng155er4.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medline (OVID)</td><td headers="hd_h_niceng155er4.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1946 – 02 April 2019</td><td headers="hd_h_niceng155er4.appb.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Exclusions</td></tr><tr><td headers="hd_h_niceng155er4.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Embase (OVID)</td><td headers="hd_h_niceng155er4.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1974 – 02 April 2019</td><td headers="hd_h_niceng155er4.appb.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Exclusions</td></tr><tr><td headers="hd_h_niceng155er4.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The Cochrane Library (Wiley)</td><td headers="hd_h_niceng155er4.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Cochrane Reviews to 2019 Issue 4 of 12</p>
|
|
<p>CENTRAL to 2019 Issue 4 of 12</p>
|
|
<p>DARE, and NHSEED to 2015 Issue 2 of 4</p>
|
|
<p>HTA to 2016 Issue 4 of 4</p>
|
|
</td><td headers="hd_h_niceng155er4.appb.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td></tr><tr><td headers="hd_h_niceng155er4.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CINAHL, Current Nursing and Allied Health Literature (EBSCO)</td><td headers="hd_h_niceng155er4.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inception – 02 April 2019</td><td headers="hd_h_niceng155er4.appb.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Exclusions</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng155er4appbtab2"><div id="niceng155er4.appb.tab2" class="table"><h3><span class="title">Medline (Ovid) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK557028/table/niceng155er4.appb.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng155er4.appb.tab2_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tinnitus/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tinnit*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 or 2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">letter/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">editorial/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">news/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp historical article/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Anecdotes as Topic/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">comment/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">case report/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(letter or comment*).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/4-11</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomized controlled trial/ or random*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12 not 13</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">animals/ not humans/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animals, Laboratory/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animal Experimentation/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Models, Animal/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Rodentia/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(rat or rats or mouse or mice).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/14-20</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 not 21</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">limit 22 to English language</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng155er4appbtab3"><div id="niceng155er4.appb.tab3" class="table"><h3><span class="title">Embase (Ovid) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK557028/table/niceng155er4.appb.tab3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng155er4.appb.tab3_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tinnitus/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tinnit*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 or 2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">letter.pt. or letter/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">note.pt.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">editorial.pt.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Case report/ or Case study/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(letter or comment*).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/4-8</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomized controlled trial/ or random*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9 not 10</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">animal/ not human/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Nonhuman/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animal Experiment/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Experimental animal/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Animal model/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Rodent/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(rat or rats or mouse or mice).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/11-18</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 not 19</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">limit 20 to English language</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng155er4appbtab4"><div id="niceng155er4.appb.tab4" class="table"><h3><span class="title">Cochrane Library (Wiley) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK557028/table/niceng155er4.appb.tab4/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng155er4.appb.tab4_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Tinnitus] explode all trees</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tinnit*:ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#1 or #2</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng155er4appbtab5"><div id="niceng155er4.appb.tab5" class="table"><h3><span class="title">CINAHL (EBSCO) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK557028/table/niceng155er4.appb.tab5/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng155er4.appb.tab5_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">S1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MH “Tinnitus”)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">S2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MH “Tinnitus Retraining Therapy”)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">S3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tinnit*</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">S4.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">S1 OR S2 OR S3</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">S5.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PT anecdote or PT audiovisual or PT bibliography or PT biography or PT book or PT book review or PT brief item or PT cartoon or PT commentary or PT computer program or PT editorial or PT games or PT glossary or PT historical material or PT interview or PT letter or PT listservs or PT masters thesis or PT obituary or PT pamphlet or PT pamphlet chapter or PT pictorial or PT poetry or PT proceedings or PT “questions and answers” or PT response or PT software or PT teaching materials or PT website</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">S6.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">S4 NOT S5</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng155er4appbtab6"><div id="niceng155er4.appb.tab6" class="table"><h3><span class="label">Table 5</span><span class="title">Database date parameters and filters used</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK557028/table/niceng155er4.appb.tab6/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng155er4.appb.tab6_lrgtbl__"><table><thead><tr><th id="hd_h_niceng155er4.appb.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Database</th><th id="hd_h_niceng155er4.appb.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dates searched</th><th id="hd_h_niceng155er4.appb.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Search filter used</th></tr></thead><tbody><tr><td headers="hd_h_niceng155er4.appb.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medline</td><td headers="hd_h_niceng155er4.appb.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2002 – 02 March 2019</td><td headers="hd_h_niceng155er4.appb.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Exclusions</p>
|
|
<p>Health economics studies</p>
|
|
<p>Quality of life studies</p>
|
|
</td></tr><tr><td headers="hd_h_niceng155er4.appb.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Embase</td><td headers="hd_h_niceng155er4.appb.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2002 – 02 March 2019</td><td headers="hd_h_niceng155er4.appb.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Exclusions</p>
|
|
<p>Health economics studies</p>
|
|
<p>Quality of life studies</p>
|
|
</td></tr><tr><td headers="hd_h_niceng155er4.appb.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Centre for Research and Dissemination (CRD)</td><td headers="hd_h_niceng155er4.appb.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>HTA - Inception – 31 Mar 2018</p>
|
|
<p>NHSEED - Inception to March 2015</p>
|
|
</td><td headers="hd_h_niceng155er4.appb.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng155er4appbtab7"><div id="niceng155er4.appb.tab7" class="table"><h3><span class="title">Medline (Ovid) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK557028/table/niceng155er4.appb.tab7/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng155er4.appb.tab7_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tinnitus/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tinnit*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 or 2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">letter/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">editorial/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">news/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp historical article/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Anecdotes as Topic/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">comment/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">case report/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(letter or comment*).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/4-11</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomized controlled trial/ or random*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12 not 13</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">animals/ not humans/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animals, Laboratory/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animal Experimentation/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Models, Animal/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Rodentia/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(rat or rats or mouse or mice).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/14-20</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 not 21</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">limit 22 to English language</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Economics/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Value of life/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp “Costs and Cost Analysis”/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Economics, Hospital/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Economics, Medical/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">29.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Economics, Nursing/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Economics, Pharmaceutical/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">31.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp “Fees and Charges”/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Budgets/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">33.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">budget*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">cost*.ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(economic* or pharmaco?economic*).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">36.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(price* or pricing*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">37.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">38.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(financ* or fee or fees).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(value adj2 (money or monetary)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/24-39</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">41.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">quality-adjusted life years/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">42.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">sickness impact profile/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">43.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(quality adj2 (wellbeing or well being)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">44.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">sickness impact profile.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">45.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">disability adjusted life.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">46.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(qal* or qtime* or qwb* or daly*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">47.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(euroqol* or eq5d* or eq 5*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(qol* or hql* or hqol* or h qol* or hrqol* or hr qol*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">49.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(health utility* or utility score* or disutilit* or utility value*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">50.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(hui or hui1 or hui2 or hui3).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(health* year* equivalent* or hye or hyes).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">52.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">discrete choice*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">53.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">rosser.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">54.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">55.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">58.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">59.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">60.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/41-59</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">61.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23 and (40 or 60)</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng155er4appbtab8"><div id="niceng155er4.appb.tab8" class="table"><h3><span class="title">Embase (Ovid) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK557028/table/niceng155er4.appb.tab8/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng155er4.appb.tab8_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tinnitus/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tinnit*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 or 2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">letter.pt. or letter/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">note.pt.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">editorial.pt.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Case report/ or Case study/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(letter or comment*).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/4-8</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomized controlled trial/ or random*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9 not 10</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">animal/ not human/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Nonhuman/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animal Experiment/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Experimental animal/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Animal model/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Rodent/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(rat or rats or mouse or mice).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/11-18</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 not 19</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">health economics/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp economic evaluation/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp health care cost/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp fee/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">budget/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">funding/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">budget*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">cost*.ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">29.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(economic* or pharmaco?economic*).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(price* or pricing*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">31.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(financ* or fee or fees).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">33.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(value adj2 (money or monetary)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/21-33</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">quality adjusted life year/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">36.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">"quality of life index"/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">37.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">short form 12/ or short form 20/ or short form 36/ or short form 8/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">38.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">sickness impact profile/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(quality adj2 (wellbeing or well being)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">sickness impact profile.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">41.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">disability adjusted life.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">42.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(qal* or qtime* or qwb* or daly*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">43.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(euroqol* or eq5d* or eq 5*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">44.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(qol* or hql* or hqol* or h qol* or hrqol* or hr qol*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">45.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(health utility* or utility score* or disutilit* or utility value*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">46.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(hui or hui1 or hui2 or hui3).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">47.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(health* year* equivalent* or hye or hyes).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">discrete choice*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">49.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">rosser.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">50.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">52.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">53.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">54.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">55.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/35-55</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20 and (34 or 56)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">58.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">limit 57 to English language</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng155er4appbtab9"><div id="niceng155er4.appb.tab9" class="table"><h3><span class="title">NHS EED and HTA (CRD) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK557028/table/niceng155er4.appb.tab9/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng155er4.appb.tab9_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH DESCRIPTOR Tinnitus EXPLODE ALL TREES</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(tinnit*)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#1 OR #2</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobniceng155er4appcfig1"><div id="niceng155er4.appc.fig1" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%201.%20Flow%20chart%20of%20clinical%20study%20selection%20for%20the%20review%20of%20what%20is%20the%20most%20clinically%20and%20cost-effective%20questionnaire%20to%20assess%20tinnitus.&p=BOOKS&id=557028_niceng155er4appcf1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK557028/bin/niceng155er4appcf1.jpg" alt="Figure 1. Flow chart of clinical study selection for the review of what is the most clinically and cost-effective questionnaire to assess tinnitus." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 1</span><span class="title">Flow chart of clinical study selection for the review of what is the most clinically and cost-effective questionnaire to assess tinnitus</span></h3></div></article><article data-type="fig" id="figobniceng155er4appgfig1"><div id="niceng155er4.appg.fig1" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%202.%20Flow%20chart%20of%20health%20economic%20study%20selection%20for%20the%20guideline.&p=BOOKS&id=557028_niceng155er4appgf1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK557028/bin/niceng155er4appgf1.jpg" alt="Figure 2. Flow chart of health economic study selection for the guideline." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 2</span><span class="title">Flow chart of health economic study selection for the guideline</span></h3><div class="caption"><p>* Non-relevant population, intervention, comparison, design or setting; non-English language</p></div></div></article><article data-type="table-wrap" id="figobniceng155er4apphtab1"><div id="niceng155er4.apph.tab1" class="table"><h3><span class="label">Table 6</span><span class="title">Studies excluded from the clinical review</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK557028/table/niceng155er4.apph.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng155er4.apph.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_niceng155er4.apph.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Reference</th><th id="hd_h_niceng155er4.apph.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Reason for exclusion</th></tr></thead><tbody><tr><td headers="hd_h_niceng155er4.apph.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Aazh 2017<a class="bibr" href="#niceng155er4.ref1" rid="niceng155er4.ref1"><sup>1</sup></a></td><td headers="hd_h_niceng155er4.apph.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No relevant outcome data; incorrect study design (survey)</td></tr><tr><td headers="hd_h_niceng155er4.apph.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Baguley 2000<a class="bibr" href="#niceng155er4.ref2" rid="niceng155er4.ref2"><sup>2</sup></a></td><td headers="hd_h_niceng155er4.apph.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No relevant outcome data</td></tr><tr><td headers="hd_h_niceng155er4.apph.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ciocon 1995<a class="bibr" href="#niceng155er4.ref3" rid="niceng155er4.ref3"><sup>3</sup></a></td><td headers="hd_h_niceng155er4.apph.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design (narrative)</td></tr><tr><td headers="hd_h_niceng155er4.apph.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Fackrell 2018<a class="bibr" href="#niceng155er4.ref5" rid="niceng155er4.ref5"><sup>5</sup></a></td><td headers="hd_h_niceng155er4.apph.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No relevant outcome data</td></tr><tr><td headers="hd_h_niceng155er4.apph.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Jüris 2013<a class="bibr" href="#niceng155er4.ref6" rid="niceng155er4.ref6"><sup>6</sup></a></td><td headers="hd_h_niceng155er4.apph.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No relevant outcome data; incorrect study design (cross-sectional study)</td></tr><tr><td headers="hd_h_niceng155er4.apph.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Newman 1996<a class="bibr" href="#niceng155er4.ref9" rid="niceng155er4.ref9"><sup>9</sup></a></td><td headers="hd_h_niceng155er4.apph.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No relevant outcome data; incorrect study design (standardization study)</td></tr><tr><td headers="hd_h_niceng155er4.apph.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Schlee 2016<a class="bibr" href="#niceng155er4.ref10" rid="niceng155er4.ref10"><sup>10</sup></a></td><td headers="hd_h_niceng155er4.apph.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No relevant outcome data; incorrect study design (observational)</td></tr><tr><td headers="hd_h_niceng155er4.apph.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Searchfield 2007<a class="bibr" href="#niceng155er4.ref11" rid="niceng155er4.ref11"><sup>11</sup></a></td><td headers="hd_h_niceng155er4.apph.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No relevant outcome data; incorrect study design (prospective cohort study)</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng155er4appitab1"><div id="niceng155er4.appi.tab1" class="table"><h3><span class="title">Criteria for selecting high-priority research recommendations</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK557028/table/niceng155er4.appi.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng155er4.appi.tab1_lrgtbl__"><table><tbody><tr><th id="hd_b_niceng155er4.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PICO question</th><td headers="hd_b_niceng155er4.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><b>Population:</b> People (children, young people and/or adults) presenting to general practice with tinnitus</p>
|
|
<p><b>Interventions:</b>
|
|
<ul><li class="half_rhythm"><div>Validated questionnaires or measure for the assessment of tinnitus severity, e.g.
|
|
<ul class="circle"><li class="half_rhythm"><div>Tinnitus questionnaire (TQ)</div></li><li class="half_rhythm"><div>Tinnitus handicap inventory (THI)</div></li><li class="half_rhythm"><div>Tinnitus handicap questionnaire (THQ)</div></li><li class="half_rhythm"><div>Tinnitus reaction questionnaire (TRQ)</div></li><li class="half_rhythm"><div>Tinnitus functional index (TFI)</div></li><li class="half_rhythm"><div>Mini TQ</div></li><li class="half_rhythm"><div>International tinnitus inventory</div></li></ul></div></li><li class="half_rhythm"><div>Published consultation tools</div></li></ul>
|
|
<b>Comparison:</b>
|
|
<ul><li class="half_rhythm"><div>Standard consultation (e.g. history taking, consultation questions and physical examination)</div></li><li class="half_rhythm"><div>Interventions compared to each other</div></li></ul>
|
|
<b>Outcomes:</b>
|
|
<ul><li class="half_rhythm"><div>Tinnitus severity (critical)- measured using validated questionnaires</div></li></ul>
|
|
Impact of tinnitus, measured using validated questionnaires: -(critical)
|
|
<ul><li class="half_rhythm"><div>Tinnitus Distress</div></li><li class="half_rhythm"><div>Tinnitus Annoyance</div></li></ul>
|
|
Health related QoL, measured using validated questionnaires: (critical)
|
|
<ul><li class="half_rhythm"><div>QoL (EQ-5D)</div></li></ul>
|
|
Tinnitus percept, measured using validated questionnaires:
|
|
<ul><li class="half_rhythm"><div>Tinnitus Loudness (important)</div></li></ul>
|
|
Other co-occurring complaints measured using validated questionnaires (important)
|
|
<ul><li class="half_rhythm"><div>Depression</div></li><li class="half_rhythm"><div>Anxiety</div></li><li class="half_rhythm"><div>Anxiety and depression</div></li><li class="half_rhythm"><div>Sleep</div></li></ul></p>
|
|
</td></tr><tr><th id="hd_b_niceng155er4.appi.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Importance to patients or the population</th><td headers="hd_b_niceng155er4.appi.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tinnitus is a highly prevalent and heterogeneous condition with no established assessment strategies for general practice. There are estimated to be over 1 million general practice appointments for tinnitus per annum<a class="bibr" href="#niceng155er4.ref12" rid="niceng155er4.ref12"><sup>12</sup></a> and a general consensus amongst patients that current tinnitus provision is unsatisfactory.<a class="bibr" href="#niceng155er4.ref7" rid="niceng155er4.ref7"><sup>7</sup></a> Therefore, better ways to assess and manage tinnitus in general practice are urgently needed. Improved general practice assessment and management of tinnitus would likely increase patient satisfaction and optimise management pathways. This should mean that more patients receive the right support and interventions in a timely fashion and therefore patient outcomes should im prove.</td></tr><tr><th id="hd_b_niceng155er4.appi.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Relevance to NICE guidance</th><td headers="hd_b_niceng155er4.appi.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">New evidence in this area may mean that future updates of the NICE Tinnitus guideline are able to make practice recommendations on how people reporting tinnitus are assessed in general practice.</td></tr><tr><th id="hd_b_niceng155er4.appi.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Relevance to the NHS</th><td headers="hd_b_niceng155er4.appi.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">McFerran et al, identified a revolving door healthcare problem with current management, with many tinnitus patients reporting multiple appointments in general practice<a class="bibr" href="#niceng155er4.ref7" rid="niceng155er4.ref7"><sup>7</sup></a>. Improved general practice management and onward referral should reduce the number of appointments per patient. May also lead to improved training for general practitioners around tinnitus or identify a training need. New evidence may identify an increased need for training healthcare professionals in general practice in how to assess people with tinnitus. For example, training may need to be conducted in how to deliver questionnaires.</td></tr><tr><th id="hd_b_niceng155er4.appi.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">National priorities</th><td headers="hd_b_niceng155er4.appi.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Department of Health’s Provision of Services for Adults with Tinnitus: A Good Practice Guide (2009) <a class="bibr" href="#niceng155er4.ref4" rid="niceng155er4.ref4"><sup>4</sup></a></div></li></ul></td></tr><tr><th id="hd_b_niceng155er4.appi.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Current evidence base</th><td headers="hd_b_niceng155er4.appi.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No evidence was identified within this guideline that investigated the use of different methods (consultation questions, examinations and questionnaires) in general practice.</td></tr><tr><th id="hd_b_niceng155er4.appi.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Equality</th><td headers="hd_b_niceng155er4.appi.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No equality issues are addressed.</td></tr><tr><th id="hd_b_niceng155er4.appi.tab1_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study design</th><td headers="hd_b_niceng155er4.appi.tab1_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Primary research in the form of randomised controlled trials, within general practice settings.</td></tr><tr><th id="hd_b_niceng155er4.appi.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Feasibility</th><td headers="hd_b_niceng155er4.appi.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The committee acknowledged that use of tinnitus questionnaires such as THI, TFI and TQ may not be feasible within a general practice appointment as completion can be time-consuming. The types of questionnaires that can be evaluated are not restricted to those listed in the ‘PICO question’ section above.</td></tr><tr><th id="hd_b_niceng155er4.appi.tab1_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other comments</th><td headers="hd_b_niceng155er4.appi.tab1_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The committee noted that general practice consultation tools have been developed for the assessment of tinnitus by NHS trusts. Assessing the effectiveness of these tools can be informative in improving the assessment of tinnitus in general practice.</td></tr><tr><th id="hd_b_niceng155er4.appi.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Importance</th><td headers="hd_b_niceng155er4.appi.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>High: the research is essential to inform future updates of key recommendations in the guideline.</div></li></ul></td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng155er4appitab2"><div id="niceng155er4.appi.tab2" class="table"><h3><span class="title">Criteria for selecting high-priority research recommendations</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK557028/table/niceng155er4.appi.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng155er4.appi.tab2_lrgtbl__"><table><tbody><tr><th id="hd_b_niceng155er4.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PICO question</th><td headers="hd_b_niceng155er4.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><b>Population:</b> Children and young people presenting to a healthcare setting with tinnitus</p>
|
|
<p>
|
|
<b>Intervention(s):</b>
|
|
</p>
|
|
<p>Development and evaluation of
|
|
<ul><li class="half_rhythm"><div>Validated questionnaires for the assessment of tinnitus severity tailored to children and young people</div></li></ul>
|
|
<b>Comparison:</b>
|
|
<ul><li class="half_rhythm"><div>Standard care (history and physical examination)</div></li><li class="half_rhythm"><div>Interventions compared to each other</div></li></ul>
|
|
<b>Outcome(s):</b>
|
|
<ul><li class="half_rhythm"><div>Tinnitus severity (critical)</div></li></ul>
|
|
Impact of tinnitus: -(critical)
|
|
<ul><li class="half_rhythm"><div>Tinnitus Distress</div></li><li class="half_rhythm"><div>Tinnitus Annoyance</div></li></ul>
|
|
Health related QoL: (critical)
|
|
<ul><li class="half_rhythm"><div>QoL (EQ-5D)</div></li></ul>
|
|
Tinnitus percept:
|
|
<ul><li class="half_rhythm"><div>Tinnitus Loudness (important)</div></li></ul>
|
|
Other co-occurring complaints (important)
|
|
<ul><li class="half_rhythm"><div>Depression</div></li><li class="half_rhythm"><div>Anxiety</div></li><li class="half_rhythm"><div>Anxiety and depression</div></li><li class="half_rhythm"><div>Sleep</div></li></ul></p>
|
|
</td></tr><tr><th id="hd_b_niceng155er4.appi.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Importance to patients or the population</th><td headers="hd_b_niceng155er4.appi.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Evidence based recommendations for questionnaires should improve decision-making for children and young people with tinnitus whereby they can potentially be offered more appropriate and timely management strategies.</td></tr><tr><th id="hd_b_niceng155er4.appi.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Relevance to NICE guidance</th><td headers="hd_b_niceng155er4.appi.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">New research of clinical and cost effectiveness would enable children and young people to receive relevant assessment of their tinnitus and allow consideration to be given to how to optimally manage their tinnitus.</td></tr><tr><th id="hd_b_niceng155er4.appi.tab2_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Relevance to the NHS</th><td headers="hd_b_niceng155er4.appi.tab2_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">New evidence may identify an increased need for training healthcare professionals in general practice in how to assess people with tinnitus. For example, training may need to be conducted in how to deliver questionnaires.</td></tr><tr><th id="hd_b_niceng155er4.appi.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">National priorities</th><td headers="hd_b_niceng155er4.appi.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None.</td></tr><tr><th id="hd_b_niceng155er4.appi.tab2_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Current evidence base</th><td headers="hd_b_niceng155er4.appi.tab2_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No evidence was identified within this guideline that investigated the use of tinnitus questionnaires for assessing tinnitus in children and young people.</td></tr><tr><th id="hd_b_niceng155er4.appi.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Equality</th><td headers="hd_b_niceng155er4.appi.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Children and young people currently do not have the same level of assessme nt for their tinnitus as adults.</td></tr><tr><th id="hd_b_niceng155er4.appi.tab2_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study design</th><td headers="hd_b_niceng155er4.appi.tab2_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised controlled trial or well-designed prospective or retrospective cohort study.</td></tr><tr><th id="hd_b_niceng155er4.appi.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Feasibility</th><td headers="hd_b_niceng155er4.appi.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This research should be feasible.</td></tr><tr><th id="hd_b_niceng155er4.appi.tab2_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other comments</th><td headers="hd_b_niceng155er4.appi.tab2_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The committee were not aware of any questionnaires for children and young people and these would need development, validation and testing.</td></tr><tr><th id="hd_b_niceng155er4.appi.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Importance</th><td headers="hd_b_niceng155er4.appi.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medium: the research is relevant to the recommendations in the guideline, but the research recommendations are not key to future updates.</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng155er4appitab3"><div id="niceng155er4.appi.tab3" class="table"><h3><span class="title">Criteria for selecting high-priority research recommendations</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK557028/table/niceng155er4.appi.tab3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng155er4.appi.tab3_lrgtbl__"><table><tbody><tr><th id="hd_b_niceng155er4.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PICO question</th><td headers="hd_b_niceng155er4.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><b>Population:</b> Children, young people and adults who have a learning disability or cognitive impairment, presenting with tinnitus</p>
|
|
<p>
|
|
<b>Intervention(s):</b>
|
|
</p>
|
|
<p>Development and evaluation of
|
|
<ul><li class="half_rhythm"><div>Validated questionnaires for the assessment of tinnitus severity tailored for people with a learning disability or cognitive impairment and tinnitus.</div></li></ul>
|
|
<b>Comparison:</b>
|
|
<ul><li class="half_rhythm"><div>Standard care (history and physical examination)</div></li><li class="half_rhythm"><div>Interventions compared to each other</div></li></ul>
|
|
<b>Outcomes:</b>
|
|
<ul><li class="half_rhythm"><div>Tinnitus severity (critical)</div></li></ul>
|
|
Impact of tinnitus: -(critical)
|
|
<ul><li class="half_rhythm"><div>Tinnitus Distress</div></li><li class="half_rhythm"><div>Tinnitus Annoyance</div></li></ul>
|
|
Health related QoL: (critical)
|
|
<ul><li class="half_rhythm"><div>QoL (EQ-5D)</div></li></ul>
|
|
Tinnitus percept:
|
|
<ul><li class="half_rhythm"><div>Tinnitus Loudness (important)</div></li></ul>
|
|
Other co-occurring complaints (important)
|
|
<ul><li class="half_rhythm"><div>Depression</div></li><li class="half_rhythm"><div>Anxiety</div></li><li class="half_rhythm"><div>Anxiety and depression</div></li><li class="half_rhythm"><div>Sleep</div></li></ul></p>
|
|
</td></tr><tr><th id="hd_b_niceng155er4.appi.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Importance to patients or the population</th><td headers="hd_b_niceng155er4.appi.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">There is currently no validated way to assess or measure tinnitus in people with a learning disability or cognitive impairment. Whilst the prevalence of tinnitus in this population is unknown, there is no reason to assume that tinnitus is less prevalent in this population. In fact, it may well be more prevalent. Therefore, there may be an unmet need that needs to be met.</td></tr><tr><th id="hd_b_niceng155er4.appi.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Relevance to NICE guidance</th><td headers="hd_b_niceng155er4.appi.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This would enable a population to receive relevant assessment of their tinnitus and allow consideration to be given to how to optimally manage tinnitus in people with a learning disability or cognitive impairment.</td></tr><tr><th id="hd_b_niceng155er4.appi.tab3_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Relevance to the NHS</th><td headers="hd_b_niceng155er4.appi.tab3_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">A validated outcome measure of tinnitus in people with a learning disability or cognitive impairment will allow NHS staff the opportunity to assess tinnitus in a population where that is currently not feasible.</td></tr><tr><th id="hd_b_niceng155er4.appi.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">National priorities</th><td headers="hd_b_niceng155er4.appi.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N /A</td></tr><tr><th id="hd_b_niceng155er4.appi.tab3_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Current evidence base</th><td headers="hd_b_niceng155er4.appi.tab3_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No evidence was identified that evaluated the use of tinnitus questionnaires for assessing tinnitus in children, young people or adults with learning disability or cognitive impairment exclusively.</td></tr><tr><th id="hd_b_niceng155er4.appi.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Equality</th><td headers="hd_b_niceng155er4.appi.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This research recommendation addresses people with a learning disability or cognitive impairment, a group that needs special consideration.</td></tr><tr><th id="hd_b_niceng155er4.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study design</th><td headers="hd_b_niceng155er4.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised controlled trial or well-designed prospective or retrospective cohort study.</td></tr><tr><th id="hd_b_niceng155er4.appi.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Feasibility</th><td headers="hd_b_niceng155er4.appi.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">There should be no feasibility issues for the research.</td></tr><tr><th id="hd_b_niceng155er4.appi.tab3_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other comments</th><td headers="hd_b_niceng155er4.appi.tab3_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The committee were not aware of any questionnaires for people with learning disabilities and cognitive impairment and these would need development, validation and testing.</td></tr><tr><th id="hd_b_niceng155er4.appi.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Importance</th><td headers="hd_b_niceng155er4.appi.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medium: the research is relevant to the recommendations in the guideline, but the research recommendations are not key to future updates.</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng155er4appitab4"><div id="niceng155er4.appi.tab4" class="table"><h3><span class="title">Criteria for selecting high-priority research recommendations</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK557028/table/niceng155er4.appi.tab4/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng155er4.appi.tab4_lrgtbl__"><table><tbody><tr><th id="hd_b_niceng155er4.appi.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PICO question</th><td headers="hd_b_niceng155er4.appi.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><b>Population:</b> Children, young people and adults who are d/Deaf or who have a severe-to-profound hearing loss</p>
|
|
<p>Validated questionnaires for the assessment of tinnitus severity, e.g.
|
|
<ul class="circle"><li class="half_rhythm"><div>Tinnitus questionnaire (TQ)</div></li><li class="half_rhythm"><div>Tinnitus handicap inventory (THI)</div></li><li class="half_rhythm"><div>Tinnitus handicap questionnaire (THQ)</div></li><li class="half_rhythm"><div>Tinnitus reaction questionnaire (TRQ)</div></li><li class="half_rhythm"><div>Tinnitus functional index (TFI)</div></li><li class="half_rhythm"><div>Mini TQ</div></li><li class="half_rhythm"><div>International tinnitus inventory</div></li></ul>
|
|
<b>Comparison:</b>
|
|
<ul><li class="half_rhythm"><div>Standard care (history and physical examination)</div></li><li class="half_rhythm"><div>Compared to each other</div></li></ul>
|
|
<b>Outcomes:</b>
|
|
<ul><li class="half_rhythm"><div>Severity (critical) -measured using validated questionnaires</div></li></ul>
|
|
Impact of tinnitus, measured using validated questionnaires: -(critical)
|
|
<ul><li class="half_rhythm"><div>Tinnitus Distress</div></li><li class="half_rhythm"><div>Tinnitus Annoyance</div></li></ul>
|
|
Health related QoL, measured using validated questionnaires: (critical)
|
|
<ul><li class="half_rhythm"><div>QoL (EQ-5D)</div></li></ul>
|
|
Tinnitus percept, measured using validated questionnaires:
|
|
<ul><li class="half_rhythm"><div>Tinnitus Loudness (important)</div></li></ul>
|
|
Other co-occurring complaints, measured using validated questionnaires (important)
|
|
<ul><li class="half_rhythm"><div>Depression</div></li><li class="half_rhythm"><div>Anxiety</div></li><li class="half_rhythm"><div>Anxiety and depression</div></li><li class="half_rhythm"><div>Sleep</div></li></ul></p>
|
|
</td></tr><tr><th id="hd_b_niceng155er4.appi.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Importance to patients or the population</th><td headers="hd_b_niceng155er4.appi.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>There is currently no validated way to assess or measure tinnitus in people who are d/Deaf or who have a severe-to-profound hearing loss.</p>
|
|
<p>Current outcome measures have been shown to also measure hearing loss or hearing difficulty as well as tinnitus. Such measures are therefore likely to be even more skewed within this population.</p>
|
|
</td></tr><tr><th id="hd_b_niceng155er4.appi.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Relevance to NICE guidance</th><td headers="hd_b_niceng155er4.appi.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This would enable a population to receive relevant assessment of their tinnitus and allow consideration to be given to how to optimally manage tinnitus in people who are d/Deaf or who have a severe-to-profound hearing loss. This should also help inform care/management plan thus reducing stress/frustration in the d/Deaf population and their carers.</td></tr><tr><th id="hd_b_niceng155er4.appi.tab4_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Relevance to the NHS</th><td headers="hd_b_niceng155er4.appi.tab4_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">A validated outcome measure of tinnitus in people who are d/Deaf or who have a severe-to-profound hearing loss will allow NHS staff the opportunity to assess tinnitus in a population where that is currently not feasible.</td></tr><tr><th id="hd_b_niceng155er4.appi.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">National priorities</th><td headers="hd_b_niceng155er4.appi.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N/A</td></tr><tr><th id="hd_b_niceng155er4.appi.tab4_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Current evidence base</th><td headers="hd_b_niceng155er4.appi.tab4_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No evidence was identified that evaluated the questionnaires or measures to assess tinnitus in people who are d/Deaf or who have a severe-to-profound hearing loss.</td></tr><tr><th id="hd_b_niceng155er4.appi.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Equality</th><td headers="hd_b_niceng155er4.appi.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This research recommendation addresses people with who are d/Deaf or who have a severe to profound hearing loss, a group that needs special consideration.</td></tr><tr><th id="hd_b_niceng155er4.appi.tab4_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study design</th><td headers="hd_b_niceng155er4.appi.tab4_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised controlled trial (RCT) or well-designed prospective or retrospective cohort study</td></tr><tr><th id="hd_b_niceng155er4.appi.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Feasibility</th><td headers="hd_b_niceng155er4.appi.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">There should be no feasibility issues for the research</td></tr><tr><th id="hd_b_niceng155er4.appi.tab4_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other comments</th><td headers="hd_b_niceng155er4.appi.tab4_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Psychometric testing of questionnaires could be undertaken to ensure validity and reliability prior to RCTs</td></tr><tr><th id="hd_b_niceng155er4.appi.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Importance</th><td headers="hd_b_niceng155er4.appi.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low: the research is of interest and will fill existing evidence gaps.</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal105 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|